In October of last year, Kailera Therapeutics unveiled a whopping $600 mill | Kailera Therapeutics and its China partner ...
Eccogene Announces Positive Topline Results from Phase 1b Trial in China of Elecoglipron (AZD5004/ECC5004), an Oral GLP-1 Receptor Agonist ...
Mean weight loss of up to 12.1% with no observed plateau at 26 weeks in Phase 2 trial in China with oral GLP-1/GIP receptor dual agonist ...
AstraZeneca (AZN) has struck an obesity drug deal with Chinese company CSPC Pharmaceutical Group (CHJTF) worth up to $18.5B ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results